Molecular epidemiology of breast cancer: Genetic variation in steroid hormone metabolism

Mutation Research - Reviews in Mutation Research

Volumn 462, Issue 2-3, 2000, Pages 323-333

  Kristensen, Vessela Nedelcheva ^a   Børresen Dale, Anne Lise ^a  

^a INSTITUTE OF CANCER RESEARCH   (Norway)

Author keywords

Breast cancer risk; CYP; Oestrogen metabolism; P450; Polymorphism

Indexed keywords

2,3,7,8 TETRACHLORODIBENZO PARA DIOXIN; 4,4' ISOPROPYLIDENEDIPHENOL; AROMATASE; CYTOCHROME P450; ENZYME; ESTRADIOL; HYDROXYSTEROID DEHYDROGENASE; PESTICIDE; POLYCHLORINATED BIPHENYL; POLYCHLORINATED DIBENZODIOXIN; POLYCYCLIC AROMATIC HYDROCARBON; STERYL SULFATASE;

AGE; BREAST CANCER; CANCER EPIDEMIOLOGY; CANCER RISK; ESTROGEN METABOLISM; FEMALE; GENETIC POLYMORPHISM; GENETIC VARIABILITY; HUMAN; PRIORITY JOURNAL; REVIEW; STEROID METABOLISM; TOBACCO;

EID: 0034068827     PISSN: 13835742     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1383-5742(00)00018-1     Document Type: Article

References (73)

1. Slip-On M.A., Bowcock A.M. BRCA1 and BRCA2 mRNA levels are coordinately elevated in human breast cancer cells in response to oestrogen. Oncogene. 13:1996;1639-1645.
2. Rannung A., Alexandrie A.K., Persson I., Ingelman-Sundberg M. Genetic polymorphism of cytochrome P4501AI, 2D6 and 2El: regulation and toxicological significance. J. Occup. Environ. Med. 37:1995;25-36.
3. Meyer U.A. Polymorphisms of human acetyltransferases. Environ. Health Perspect. 102:1994;213-216.
4. Pemble S., Schroeder K.R., Spencer S.K., Meyer D.J., Hallier E., Bolt H., Ketterer B., Taylor J.B. Human glutathione S-transferase theta (GSTTl): cDNA cloning and the characterization of a genetic polymorphism. Biochern L. 300:1994;271-276.
5. Sarhanis P., Redman C., Perrett C., Brannigan K., Clayton R.N., Hand P., Musgrove C., Suarez V., Jones P., Fryer A.A., Farrell W.E., Strange R.C. Epithelial ovarian cancer: influence of polymorphism at the gluthatione-S-transferase GSTM1 and GSTTI loci on p53 expression. Br. J. Cancer. 74:1996;1757-1761.
6. Hartman A., Blaszyk H., Kovach J.S., Sommer S. The molecular epidemiology of P53 gene mutations in human breast cancer. Trends Genet. 13:1997;27-33.
7. Hankinson S.E., Willett W.C., Manson J.E., Colditz G.A., Hunter D.J., Spiegelman D., Barbieri R.L., Speizer F.E. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J. Nat. Cancer Inst. 90:1998;1292-1299.
8. Hurd C., Khattree N., Dinda S., Alban R., Moudgil V.K. Regulation of tumour suppressor protein, p53 and retinoblastoma, by estrogen and antiestrogens in breast cancer cells. Oncogene. 15:1997;991-995.
9. Pratt M.A., Satkunaratnam A., Novosad D.M. Estrogen activates raf-1 kinase and induces expression of Egr-1 in MCF-7 breast cancer cells. Mol. Cell. Biochem. 189:1998;119-125.
10. Kasid D., Lipman L. Regulation of growth factors by estrogen through the estrogen receptor. J. Steroid. Biochem. 27:1987;465-470.
11. Hsu C.L., Kirkman B.R., Fishman J. Differential expression of oncogenes c-fos, cmyc and Her-2/neu induced by estradiol and 16α hydroxyestrone in human breast cancer cell line and the progesterone receptor. J. Steroid. Biochem. 87:1991;184-190.
12. Tesarik J., Garrigosa L., Mendoza C. Estradiol modulates breast cancer cell apoptosis: a novel nongenomic steroid action relevant to carcinogenesis. Steroids. 64:1999;22-27.
13. Lapointe J., Fournier A., Richard V., Labrie C. Androgens downregulate bcl-2 protooncogene expression in ZR-75-1 human breast cancer cells. Endocrinology. 140:1999;416-421.
14. Dees C., Foster J.S., Ahamed S., Wimalasena J. Dietary estrogens stimulate human breast cells to enter the cell cycle. Environ. Health Perspect. 105:1997;633-636.
15. Ingram D., Sanders K., Kolybaba M., Lopez D. Case control study of phytoestrogens and breast cancer. The Lancet. 350:1997;990-994.
16. N. Gharany, D.M. Waterworth, S. Batty, D. White, C. Gilling-Smith, G.S. Conway, M. McCarthy, S. Franks, R. Williamson, Association of the steroid synthesis gene CYP11α with polycystic ovary syndrome and hyperandrogenism, Human Mol. Genet., (1997) 397-402.
17. Burak W.E. Jr., Quinn A.L., Farrar W.B., Brueggerneier R.W. Androgens influence estrogen induced responses in human breast carcinoma cells through cytochrome P450. Breast Cancer Res. Treat. 44:1997;57-64.
18. Durocher R., Morissette J., Simard J. Genetic linkage mapping of the CYP1A1 gene encoding the cholesterol side chain cleavage P450scc close to the CYP1A1 gene and D15S204 in the chromosome 15q22.33-q23 region. Pharmacogenetics. 8:1998;49-53.
19. Voutilainen R., Miller W.L. Developmental expression of genes for steroidogenic enzymes P450scc [20,22-desmolase], P450c17 [17 alpha-hydroxylase/17,20 lyase], and P450c21 [21-hydroxylase] in the human fetus. J. Clin. Endocrinol. Metab. 63:1986;1145-1150.
20. Picardo-Leonard J., Miller W.L. Cloning and sequence of the human gene for p450c17 [steroid 17a-hydroxylase/17,20 lyase]: similarity with the gene for P450c21. DNA. 6:1987;439-448.
21. Carey A.H., Chan K.L., Short F., White D., Williamson R., Franks S. Evidence for a single gene effect causing polycystic ovaries and male pattern baldness. Clin. Endocrinol. 38:1993;653-658.
22. Feigelson H.S., Coetzee G.A., Kolonel L.X., Ross R.K., Henderson B.E. A polymorphism in the CYP17 gene increases the risk of breast cancer. Cancer Res. 57:1997;1063.
23. Feigelson H.S., Shames L.S., Pike M.C., Coetzee G.A., Stanczyk F.Z., Henderson B.E. Cytochrome p450c 17α gene (CYP17) polymorphism is associated with serum estrogen and progesterone concentrations. Cancer Res. 58:1998;585-587.
24. Kadonada J.T., Carner K.R., Masiarz F.R., Tjan R. Isolation of cDNA encoding transcription factor Sp1 and functional analysis of the DNA binding domain. Cell. 51:1987;1079-1090.
25. Nedelcheva Kristensen V., Haraldsen E.K., Andersson K.B., Lønning P.E., Erikstein B., Kåresen R., Gabrielsen O.S., Børresen-Dale A.L. CYP17 and breast cancer The polymorphism in the 5′ flanking area of CYP17 does not influence binding to SP-1. Cancer Res. 59:1999;2825-2828.
26. Weston A., Pan C.-F., Bleiweiss I.J., Ksieski H.B., Roy N., Maloney N., Wolf M.S. CYP17 genotype and breast cancer risk. Cancer Epidemiol. Biomarkers Prev. 7:1998;941-945.
27. Helzlsouer K.J., Huang H.-Y., Strickland P.T., Hoffman S.H., Alberg A.J., Comstock G.W., Bell D. Association between CYP17 polymorphisms and the development of breast cancer. Cancer Epidemiol. Biomarkers Prev. 7:1998;945-951.
28. Nakajin S., Shinoda M., Haniu M., Shively J.E., Hall P.F. C21 steroid side chain cleavage enzyme from porcine adrenal microsomes: purification and characterisation of the 17a hydroxylase/C17,20-lyase cytochrome P450. J. Biol. Chem. 259:1984;3971-3976.
29. Yang K., Khalil M.W., Strutt B.J., Killinger D.W. 11β Hydroxysteroid dehydrogenase 1 activity and gene expression in human adipose stromal cells: effect on aromatase activity. J. Steroid. Biochem. Molec. Biol. 60:1997;247-253.
30. Hankinson S.E., Willett W.C., Manson J.E., Colditz G.A., Hunter D.J., Spiegelman D., Barbieri R.L., Speizer F.E. Plasma sex steroid hormone levels and risk of breast cancer in postmenopausal women. J. Nat. Cancer Inst. 90:1998;1292-1299.
31. Pike M.C., Spicer D.V., Dagmoush L., Press M.F. Estrogens, progestogens, normal breast cell proliferation, and breast cancer risk. Epidemiol. Rev. 15:1993;17-35.
32. Means G.D., Mahendroo M.S., Corbin C.J., Mathis J.M., Powell F.E., Mendelson C.R., Simpson E.R. Structural analysis of the gene encoding human aromatase cytochrome P450, the enzyme responsible for estrogen biosynthesis. J. Biol. Chem. 264:1989;19386-19391.
33. Harada N., Ogawa H., Shozu M., Yamada K. Genetic studies to characterise the origin of mutation in placental aromatase deficiency. Am. J. Hum. Genet. 51:1992;666-672.
34. Fisher C.R., Graves K.H., Parlow A.F., Simpson E.R. Characterization of mice deficient in aromatase [ArKo] because of targeted disruption of the cyp 19 gene. Proc. Natl. Acad. Sci. USA. 95:1998;6965-6970.
35. Mahendroo M.S., Mendelson C.R., Simpson E.R. Tissue specific and hormonally controlled alternative promoters regulate aromatase cytochrome P450 gene expression in human adipose tissue. J. Biol. Chem. 268:1993;19463-19470.
36. Harada N., Utsumi T., Takagi Y. Tissue specific expression of the human aromatase cytochrome P450 gene by alternative use of multiple exons and promoters, and switching of tissue specific exons 1 in carcinogenesis. Proc. Natl. Acad. Sci. USA. 90:1993;11312-11316.
37. Harada N., Utsumi T., Tagaki Y. Molecular and epidemiological analyses of abnormal expression of aromatase in breast cancer. Pharmacogenetics. 5:1995;59-64.
38. Sourdaine P., Parker M.G., Telford J., Miller W.R. Analysis of the aromatase cytochrome P450 gene in human breast cancers. J. Mol. Endocrinol. 13:1994;331-337.
39. Siegelmann-Danielli N., Buetow K.H. Constitutional genetic variation at the human aromatase gene (CYP19) and breast cancer risk. Br. J. Cancer. 79:1999;456-463.
40. Polymeropoulos M.H., Xiao H., Rath D.S., Merril C.R. Tetranucleotide repeat polymorphism at the human aromatase cytochrome p450 gene (CYP19). Nucleic Acids Res. 19:1991;195.
41. Wooster R., Cleton-Jansen A.-M., Collins N., Mangion, Cornelis R.S., Cooper C.S., Gustersun B.A., Ponder B.J.A., von Deimling A., Wiestler O.D., Cornelisse C.J., Devilee P., Stratton M.R. Instability of short tandem repeats (microsatellites) in human cancers. Nat. Genet. 6:1994;152-156.
42. Zhang L., Leeflang E.P., Yu J., Arnheim N. Studying human mutations by sperm typing: instability of CAG trinucleotide repeats in the human androgen receptor gene. Nat. Genet. 7:1994;531-535.
43. Nedelcheva Kristensen V., Børresen-Dale A.L. Improved electrophoretic separation of polymorphic short tandem repeats using bis-benzimide. BioTechniques. 23:1997;634.
44. Nedelcheva Kristensen V., Andersen T.-L., Lindblom A., Nesland J., Olsen A., Børresen-Dale A.L. A rare CYP19 (aromatase) variant may increase the risk of breast cancer. Pharmacogenetics. 8:1998;43-48.
45. Kristensen T., Nedelcheva Kristensen V., Børresen-Dale A.L. High throughput screening for known mutations by automated analysis of single sequencing reactions (SSR). BioTechniques. 24:1998;832-835.
46. Mannermaa A., Peltoketo H., Winqvist R., Ponder B., Kiviniemi H., Easton D.F., Poutanen M., Isomaa V., Vihko R. Human familial and sporadic breast cancer: analysis of the coding regions of the 17β-steroid dehydrogenase 2 gene (EDH17B2) using a single strand conformation polymorphism assay. Hum. Genet. 93:1994;319-324.
47. Friedman L.S., Lynch E.D., King M.C. Two independent polymorphisms at the 17β-hydroxysteroid dehydrogenase (EDH 1713) gene (17q21). Hum. Molec. Genet. 2:1993;821.
48. Hoch R.V., Thompson D.A., Baker R.J., Weigel R.J. GATA-3 is expressed in association with estrogen receptor in breast cancer. Int. J. Cancer. 84:1999;122-128.
49. Utsumi T., Yoshimura N., Takeuchi S., Ando L., Maruta M., Maeda M., Harada N. Steroid sulphatase expression is an independent predictor of recurrence in human breast cancer. Cancer Res. 59:1999;377-381.
50. Martucci C.R., Fishman J. P450 of estrogen metabolism. Pharmac. Ther. 57:1993;237-257.
51. Cavalieri E.L., Stack D.E., Devanesen P.D., Todorovic R., Dwivedi I., Higginbotham S., Johansson S.L., Patil K.D., Gross M.L., Gooden J.K., Ramanathan R., Cerny R.L., Rogan E.G. Molecular origin of cancer: catechol estrogen-3,4-quinones as endogenous tumour initiators. Proc. Natl. Acad. Sci. USA. 94:1997;10937-10942.
52. Gupta M., McDougal A., Safe S. Estrogenic and antiestrogenic activities of 16alpha- and 2-hydroxy metabolites of 17beta-estradiol in MCF-7 and T47D human breast cancer cells. J. Steroid Biochem. Mol. Biol. 67:1998;413-419.
53. Lemon H.M., Reilly D. Genotypic variations in Caucasian leukocyte estradiol 16 hydroxylase activity: a measurable determinant of breast cancer risk? Nebr. Med. J. 59:1974;151-155.
54. Osborne M.P., Bradlow H.L., Wong Y.C., Telang N.T. Upregulation of estradiol C-16 hydroxylation in human breast tissue: a potential biomarker of breast cancer risk. J. Nat. Cancer Inst. 85:1993;1917-1921.
55. Bradlow H.L., Devis D.L., Lin G., Sepkovic D., Tiwari R. Effects of pesticides on the ratio of 16a/2 hydroxyestrone: a biologic marker of breast cancer risk. Environ. Health Perspect. 103:1995;147-149.
56. Stoilov L., Akarsu A.N., Alozie L., Child A., Barsoum Homsy M., Turacli M.E., Or M., Lewis R., Ozdemir N., Brice G., Aktan G., Chevrette L., Coca-Prados M., Sarfarazi M. Sequencing analysis and homology modelling suggest that primary congenital glaucoma on 2p21 results from mutations disrupting either the hinge region or the conserved core structures of cytochrome P4501B1. Am. J. Hum. Genet. 62:1998;573-584.
57. Hayes C.L., Spink D.C., Spink B.C., Cao J.Q., Walker N.J., Sutter T.R. 17b-Estradiol hydroxylation catalyzed by human cytochrome P4501B1. Proc. Natl. Acad. Sci. USA. 93:1996;9776-9781.
58. Shimada T., Hayes C.L., Yamazaki H., Amin S., Hecht S.S., Guengerich F.P., Stutter T.R. Activation of chemically diverse procarcinogens by human cytochrome P4501B1. Cancer Res. 56:1996;2979-2984.
59. Hellmold H., Rylander T., Magnusson M., Reilmer E., Warner M., Gustafsson J.-A. Characterization of cytochrome P450 enzymes in human breast cancer tissue from reduction mammaplasties. J. Clin. Endocrinol. Metab. 83:1998;886-895.
60. Larsen M.C., Angus W.G.R., Brake P.R., Elton S.E., Sukow K.A., Jefcoate C.R. Characterization of CYP1B1 and CYP1A1 expression in human mammary epithelial cells: role of the aryl hydrocarbon receptor in polycyclic aromatic hydrocarbon metabolism. Cancer Res. 58:1998;2366-2374.
61. Murray G.I., Taylor M.C., McFadyen C.E., McKay J.A., Greenlee W.F., Bruke M.D., Melvin W.T. Tumour specific expression of cytochrome P450 CYP1B1. Cancer Res. 57:1997;3026-3031.
62. Bailey L.R., Roodi N., Dupont W.D., Parl F.F. Association of cytochrome P4501B1 (CYP1B1) polymorphism with steroid receptor status in breast cancer. Cancer Res. 58:1998;5038-5041.
63. Nedelcheva V., Gut I. Cytochromes P450 in the rat and man: methods of investigation, substrate specificities and relevance to cancer. Xenobiotica. 24(12):1994;115.
64. Marchand L.L., Sivaraman L., Pierce L., Seifried A., Lum A., Wilkens L.R., Lau A.F. Associations of CYP1A1 GSTM1 and CYP2E1 polymorphisms with lung cancer suggest cell type specificities to tobacco carcinogens. Cancer Res. 58:1998;4858-4863.
65. Kawajiri K., Eguchi H., Nakachi K., Sekiya T., Yamamoto M. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res. 56:1996;72-76.
66. Zhang Z.Y., Fasco M.J., Huang L., Guengerich F.P., Kaminsky L.S. Characterization of purified human recombinant cytochrome P4501A1-1le 462 and Val462: assessment of a role for the rare allele in carcinogenesis. Cancer Res. 56:1996;3926-3933.
67. Ishibe N., Hankinson S.E., Colditz G.A., Spiegelman D., Willett W.C., Speizer R.E., Kelsey K.T., Hunter D.J. Cigarette smoking, cytochrome P4501A1 polymorphisms and breast cancer risk in the nurses' health study. Cancer Res. 58:1998;667-671.
68. Taioli E., Bradlow H.L., Garbes S.V., Sepkovic D.W., Osborne M.P., Trachman L., Ganguly S., Garte S.J. Role of estradiol metabolism and CYP1A1 polymorphisms in breast cancer risk. Cancer Detect Prev. 23:1999;232-237.
69. Liu H., Wormke M., Safe S.H., Bjeldanes L.F. Indolo[3,2-b]carbazole: a dietary derived factor that exhibits both antiestrogenic and estrogenic activity. J. Nat. Cancer Inst. 86:1994;1758-1765.
70. Ricci M.S., Toscano D.G., Mattingly C.J., Toscano W.A. Jr. Estrogen receptor reduces CYP1A1 induction in cultured human endometrial cells. J. Biol. Chem. 274:1999;3430-3438.
71. Wang W.L., Thomsen J.S., Porter W., Moore M., Safe S. Effect of transient expression of the estrogen receptor on constitutive and inducible CYP 1A1 in Hs578T human breast cancer cells. Br. J. Cancer. 73:1996;316-322.
72. Watanabe J., Harada N., Suemasu K., Higashi Y., Gotoh O., Kawajiri K. Arginine-cysteine polymorphism at codon 264 of the human CYP19 gene does not affect aromatase activity. Pharmacogenetic. 5:1997;419-425.
73. Nedelcheva Kristensen V., Harada N., Haraldsen E., Yoshimura N., Lønning P.E., Erikstein B., Karesen R., Kristensen T., Børresen-Dale A.-L. Genetic variants of CYP19 (aromatase) and breast cancer risk. Oncogene. 19:2000.